Company Overview and News

6
UK’s CDC Group invests in IDFC Alternatives

2018-06-07 livemint
Mumbai: IDFC Ltd has brought in the UK’s CDC Group as an investor in the third private equity (PE) fund managed by its alternative asset management business IDFC Alternatives Ltd, two people aware of the development said. CDC’s entry provides an exit to some of the existing limited partners (LPs) of IDFC Alternatives.
SIFLY 523756 SRI 533271 HDB SREINFRA 500180 ASHOKA HDFCBANK SRIA

0
Ashoka Buildcon Limited - Shareholders meeting

2018-06-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533271 ASHOKA

0
Ashoka Buildcon Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533271 ASHOKA

0
Ashoka Buildcon Limited - Shareholders meeting

2018-06-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533271 ASHOKA

0
Ashoka Buildcon Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533271 ASHOKA

0
Ashoka Buildcon Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533271 ASHOKA

0
Ashoka Buildcon Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533271 ASHOKA

0
Ashoka Buildcon Limited - Outcome of Board Meeting

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533271 ASHOKA

0
Ashoka Buildcon Limited - Press Release

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533271 ASHOKA

0
Ashoka Buildcon Limited - Bonus

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533271 ASHOKA

0
Ashoka Buildcon Limited - Financial Result Updates

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533271 ASHOKA

7
BHEL, BEL, Coal India, BPCL, IOB results eyed

2018-05-28 thehindubusinessline
Apollo Microsystems, Asahi Songwon Colours, Ashoka Buildcon, Balmer Lawrie, Bedmutha, BEL, BHEL, BPCL, Coal India, Cochin Minerals, Datamatics, Deccan Cement, Dish TV, D-Link India, Force Motors, Galaxy Surfactants, Glenmark Pharma, IOB, Ipca Laboratories, Jyothi, M&M, Max India, MMTC, Parsvanath, Sundram Brake, Thomas Cook, TTK Health, Unichem Labs, Uttam Sugar and Zenith Exports are some of the companies that will declare their Q4/FY results on Tuesday.
IPCALAB 500413 523319 533271 FORCEMOT BALMLAWRIE ASHOKA ZENITHEXPO 533278 THOMASCOOK 512553 500271 524494 MAX CLNDY COALINDIA 500033 MXGQY

0
Ashoka Buildcon arm gets ₹383.80-cr arbitral award

2018-05-25 thehindubusinessline
Ashoka Buildcon on Thursday said its subsidiary has received an arbitral award of ₹383.80 crore against various claims filed by it. Ashoka Infrastructure (SPV), which had executed the Pune-Shirur Road Project in Maharashtra, has received an arbitral award, Ashoka Buildcon informed the exchanges.
533271 GAILY ASHOKA GAILF

0
Ashoka Buildcon Limited - Updates

2018-05-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
533271 ASHOKA

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...